LCL-161, Inhibitor

LCL-161

Cat. Num. AAA385020

• Purity: >98%
• Synonyms: LCL-161; LCL161; LCL 161; inhibitor

• Purity/Purification: >98%
• Form/Format: Powder
• Concentration: 0.1 mM: 19.99 mL (1 mg); 99.96 mL (5 mg); 199.92mL (10 mg); 0.5 mM: 4 mL (1 mg); 19.99 mL (5 mg); 39.98 mL (10 mg); 1 mM: 2 mL (1 mg); 10 mL (5 mg); 19.99 mL (10 mg); 5 mM: 0.4 mL (1 mg); 2 mL (5 mg); 4 mL (10 mg) (varies by lot)

• CAS Number: 1005342-46-0
• Formula: C26H33FN4O3S
• SMILES: C[C@@H](C(=O)N[C@@H](C1CCCCC1)C(=O)N2CCC[C@H]2C3=NC(=CS3)C(=O)C4=CC=C(C=C4)F)NC
• Actions: Antagonist
• Solubility (DMSO): 100 mg/mL (199.74 mM)
• Solubility (Ethanol): 20 mg/mL heating (39.94 mM)
• Solubility (Water): <1 mg/mL (<1 mM)
• Availability: We cannot ship this item to Switzerland, Italy, Germany, France and Austria.
• Preparation and Storage: at -20 degree C 3 years Powder

Chemical Structure

Related Product Information for LCL-161, inhibitor

LCL161 is an orally bioavailable second mitochondrial-derived activator of caspases (SMAC) mimetic and inhibitor of IAP (Inhibitor of Apoptosis Protein) family of proteins, with potential antineoplastic activity.

References

Choi SW, .et al. PELI1 Selectively Targets Kinase-Active RIP3 for Ubiquitylation-Dependent Proteasomal Degradation, Mol Cell, 2018, Jun 7;70(5):920-935.e7 PMID: 29883609
Han-Hee Park, .et al. HS-1371, a novel kinase inhibitor of RIP3-mediated necroptosis, Exp Mol Med, 2018, Sep; 50(9): 125 PMID: 30237400
Gi-Bang Koo, .et al. Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics, Cell Res, 2015, Jun; 25(6): 707-725 PMID: 25952668
Kim SK, .et al. Upregulated RIP3 Expression Potentiates MLKL Phosphorylation-Mediated Programmed Necrosis in Toxic Epidermal Necrolysis, J Invest Dermatol, 2015, Aug;135(8):2021-2030 PMID: 25748555